Please register for this webinar here.
From breakthrough sciences to transformative therapies, cell and gene therapy is changing what’s possible in medicine. But where is the field heading next - and what does it mean for investors? Join a VC Fireside Chat with 3 prominent figures in this space, as we unpack the trends, opportunities, and challenges shaping the next generation of cell and gene therapies. Meet the investors bringing their perspective to the conversation:
Borja Ruiz is a Medical Doctor, Board-Certified Cardiologist and MBA graduate from London Business School. He is a Principal at Invivo Ventures, the venture capital arm of Invivo Partners, where he focusses on identifying, evaluating and supporting innovative biotechnology companies across europe. Prior to venture capital, he trained and practiced cardiology, contributing to clinical research in cardiovascular disease, and gained experience working with pharmaceutical and healthcare organisations.
Daniel Sieiro joined Soffinova Partners in 2023 as Senior Associate in the Capital Strategy team. Prior to joining Soffinova, he was a Principal at Plexus Ventures, where he focussed on business development and partnering transactions across the healthcare sector, including cell and gene therapy and precision oncology. Before moving into industry, Daniel was a research fellow at Harvard Medical School and Brigham and Women’s Hospital.
Emeric Nouailhac joined Angelini Ventures as an investor in July 2026. Prior to this, he spent two years at Wellington Partners, supporting life sciences investments and working closely with portfolio companies through Board Observer roles. Earlier, he gained investment experience at Andera Partners and Bpifrance Large Venture. Emeric holds a PharmD from Universite Paris Cite, and a Master’s in Management from ESSEC Business School.
💡 We will explore:
Where gene and cell therapy is heading and what is attracting investor interest
How VCs evaluate opportunities across science, technology and development
What makes a GCT program investment-ready
Financing challenges, timelines and value inflection points in GCT
What founders, scientists and translational teams should consider when approaching investors
Opportunities and challenges shaping the next generation of GCT companies
GCT programs require more capital, longer timelines and multiple financing rounds before clinical validation, making it essential to understand how investors think. Whether you are a founder, scientist considering a spin-off, or part of a tech transfer or translational team, this session offers candid, practical insights from the investors’ side of the table. Bring your questions to the live Q&A!